Divide a valuation of more than $2bn by $125m of 2025 revenue [1][4] and the floor is about 16 times sales [2], which reads expensive until you run the same sum on the Series D that closed in September 2025, where a valuation just past $1bn sat on 2024 revenue of roughly $25m [10][1], or about 40 times [3]. The valuation doubled; the price per dollar of revenue fell by something like 60% [4]. Morgan Health, JPMorgan Chase's employer-healthcare investment arm [2], paid up for growth that had already been banked rather than growth it has to underwrite.
That comparison is the cleanest one available, even if it isn't a fair one: the Series D priced in September with three quarters of a five-fold year already visible, so 40 times trailing flatters the compression. The direction survives the caveat. What survives it less comfortably is the unit economics underneath. Revenue of $125m against $7bn of oncology spend under management is a take rate of about 1.79% [4][9][6], and at the 80,000 patients disclosed in September, $5bn of managed spend works out to roughly $62,500 per patient per year [9][10] against something like $1,560 of Thyme Care revenue per patient [7]. Thin slices of very large numbers can compound beautifully, and they can also be repriced by a single payer at renewal.
The market arithmetic is the harder constraint. The value-based oncology market is put at $20.5bn this year, reaching $28bn by 2031 at 6.4% a year [11], which is a total expansion of about 36.6% over five years against revenue that grew 400% in one [11]. At $125m, Thyme Care holds about 0.61% of that market [8]; another five-fold run would put it near $625m, or roughly 2.2% of the 2031 pool [9]. Growth of that shape comes from taking contracts off incumbents, not from the tide.
Which is what makes the second announcement the interesting one. Thyme Care does not diagnose or treat; it coordinates the gaps between appointments for plans and providers holding financial risk [8], deliberately outside the lane where Waiv raised $33m to read biomarkers off pathology slides and Gosta Labs took a 7.5m euro seed for oncologist documentation [12]. Now a new parent, Thyme Companies, will build standalone biosimilar-adoption and clinical-trial-recruitment businesses that the navigation platform does not address [5]. That is management attention and capital going somewhere other than deepening the book that produced the 16 times multiple, and the leadership handoff, with Brad Diephuis taking the CEO seat on 1 September 2026 and founder Robin Shah moving to executive chairman [7], reads as the staffing plan for exactly that split.
This is probably wrong, but the multiple looks defensible and the profitability claim does not. On roughly $400m raised in total [5], a company reporting profit and positive free cash flow at $125m of revenue [4] is asserting care-team margins that nobody outside has audited. What would settle it is an audited statement, disclosure of how concentrated the payer book is when CVS Health Ventures and Humana sit on the cap table as well as the other side of the contract [3], and clarity on whether Thyme Companies is funded from operating cash or from the Series E. Any of those going the wrong way, and 16 times sales stops looking like a value and starts looking like just a price.
